On June 16, 2026, Phase III clinical data for therapeutic neoantigen cancer vaccines has revealed a 50% reduction in recurrence rates for advanced melanoma. Unlike preventive vaccines, therapeutic cancer vaccines are custom-manufactured to train the patient's immune system to attack existing tumor cells by targeting tumor-specific neoantigens.

At Onco Medicine, we are preparing our specialized cold chain distribution network to support these customized cellular vaccines. Maintaining temperature integrity for personalized biologics is critical for clinical success.

Why Neoantigen Vaccines are Succeeding in 2026

• Patient-Specific Design: Next-generation sequencing identifies mutations unique to the patient's tumor, allowing algorithms to select the most immunogenic neoantigens for the vaccine.
• Broad Immune Response: Vaccines are formulated with multiple distinct peptides or mRNA sequences, prompting the immune system to launch a multi-targeted attack.
• Synergistic Combinations: Administering neoantigen vaccines alongside checkpoint inhibitors like pembrolizumab increases T-cell activation and tumor clearance.

Harnessing the immune system is the ultimate goal of oncology. Therapeutic neoantigen vaccines represent a monumental leap toward a cure, offering a highly personalized, non-toxic approach to eliminating residual cancer cells. Onco Medicine is proud to support the clinical networks bringing these next-generation genetic tools to the forefront of patient care.